The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

onconova.com

Founded Year

1998

Stage

IPO | IPO

Total Raised

$165.63M

Date of IPO

7/25/2013

Market Cap

0.02B

Stock Price

1.09

Revenue

$0000 

About Onconova Therapeutics

Onconova Therapeutics, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drug candidates to treat cancer. The companys clinical-stage product candidates include Rigosertib IV, which is in Phase III clinical trials for patients with higher risk myelodysplastic syndromes (MDS); Rigosertib oral in combination with azacitidine that is in Phase II clinical trials for patients with MDS and acute myelogenous leukemia; and Rigosertib oral, which is in Phase II clinical trials for patients with lower risk MDS. Its clinical-stage product candidates also comprise Briciclib, which is in Phase I multisite dose-escalation trial for patients with advanced solid tumors; and Recilisib that has completed four Phase I clinical trials for patients with acute radiation syndromes. In addition, the company has various product candidates that target kinases, cellular metabolism, or cell division in preclinical development.

Onconova Therapeutics Headquarter Location

375 Pheasant Run

Newtown, Pennsylvania, 18940,

United States

267-759-3680

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Onconova Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Onconova Therapeutics is included in 2 Expert Collections, including Cancer.

C

Cancer

4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Onconova Therapeutics Patents

Onconova Therapeutics has filed 12 patents.

The 3 most popular patent topics include:

  • Experimental cancer drugs
  • Fluoroarenes
  • Abandoned drugs
patents chart

Application Date

Grant Date

Title

Related Topics

Status

12/6/2013

3/3/2020

Transcription factors, Oncology, Rare diseases, Experimental cancer drugs, Antineoplastic drugs

Grant

Application Date

12/6/2013

Grant Date

3/3/2020

Title

Related Topics

Transcription factors, Oncology, Rare diseases, Experimental cancer drugs, Antineoplastic drugs

Status

Grant

Latest Onconova Therapeutics News

Onconova Therapeutics Announces Acceptance of Abstract for Publication at the ASCO Annual Meeting

Apr 27, 2022

About Onconova Therapeutics Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer. The Company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Onconova’s novel, proprietary multi-kinase inhibitor narazaciclib (formerly ON 123300) is being evaluated in two separate and complementary Phase 1 dose-escalation and expansion studies. These trials are currently underway in the United States and China. Onconova’s product candidate rigosertib is being studied in an investigator-sponsored study program, including in a dose-escalation and expansion Phase 1/2a investigator-sponsored study with oral rigosertib in combination with nivolumab for patients with KRAS+ non-small cell lung cancer. For more information, please visit www.onconova.com . Forward-Looking Statements Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, and involve risks and uncertainties. These statements relate to Onconova’s expectations regarding the timing of Onconova’s and investigator-initiated clinical development and data presentation plans, and the mechanisms and indications for Onconova’s product candidates. Onconova has attempted to identify forward-looking statements by terminology including "believes," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should," “preliminary,” “encouraging,” "approximately" or other words that convey uncertainty of future events or outcomes. Although Onconova believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including the success and timing of Onconova's clinical trials, investigator-initiated trials and regulatory agency and institutional review board approvals of protocols, Onconova’s collaborations, market conditions and those discussed under the heading "Risk Factors" in Onconova's most recent Annual Report on Form 10-K and quarterly reports on Form 10-Q. Any forward-looking statements contained in this release speak only as of its date. Onconova undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events. Company Contact:

Onconova Therapeutics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Onconova Therapeutics Rank

  • When was Onconova Therapeutics founded?

    Onconova Therapeutics was founded in 1998.

  • Where is Onconova Therapeutics's headquarters?

    Onconova Therapeutics's headquarters is located at 375 Pheasant Run, Newtown.

  • What is Onconova Therapeutics's latest funding round?

    Onconova Therapeutics's latest funding round is IPO.

  • How much did Onconova Therapeutics raise?

    Onconova Therapeutics raised a total of $165.63M.

  • Who are Onconova Therapeutics's competitors?

    Competitors of Onconova Therapeutics include Kiadis Pharma, Aquinox Pharmaceuticals, Neuraltus Pharmaceuticals, Radius Health, TetraLogic Pharmaceuticals and 13 more.

You May Also Like

N
Neuraltus Pharmaceuticals

Neuraltus Pharmaceuticals is a privately-held biopharmaceutical company dedicated to developing and commercializing innovative therapeutics that address critical unmet needs for patients and physicians in the treatment of neurodegenerative diseases. The Company is collaborating with global ALS specialists and seeking input from patient advocacy organizations to help inform the clinical development path and better understand the needs of people affected by the disease.

C
Cardeon Corporation

Cardeon Corporation is engaged in developing solutions for stroke prevention

F
Functional Genetics

FGI, based in Rockville, Maryland, is developing drugs and diagnostics based on its genome-wide discovery and validation of genes and their roles in human disease. FGI has validated drug candidates for the treatment of infectious disease, drug resistant cancer and Alzheimer's disease.

H
Humanetics Corporation

Humanetics Corporation is a clinical-stage pharmaceutical company engaged in developing and commercializing products to enhance human health and wellbeing in markets with urgent and unmet needs with a focus on radiation modulators for oncology, medical imaging and medical countermeasure uses.

M
Mimetix Pharmaceuticals

Free Radical Scavengers developed from Duke's BME Department for treating and preventing diseases from occurring.

E
Esperance Pharmaceuticals

Esperance Pharmaceuticals develops targeted anticancer drugs that selectively kill cancer cells without harming normal cells.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.